Medicine Information

Edjenta

Name: Edjenta
Brand: Edjenta
Rating: 4.5 (117 reviews)

Tablet5 mgAnti-diabeticATC: A10BK03

Generic Name

Empagliflozin

Manufacturer

Incepta Pharmaceuticals Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
edjenta 5 mg tablet	৳ 20.00	N/A

Description

Overview of the medicine

Edjenta 5 mg tablet contains Empagliflozin, an SGLT2 inhibitor used to lower blood glucose in adults with type 2 diabetes mellitus. It also reduces the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or heart failure.

Uses & Indications

To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.

To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (HFrEF or HFpEF).

To reduce the risk of kidney disease progression, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease.

Dosage

Adults

Initial dose is 10 mg once daily, in the morning, with or without food. May be increased to 25 mg once daily if additional glycemic control is needed and 10 mg is well tolerated. For heart failure or chronic kidney disease, 10 mg once daily.

Elderly

No dose adjustment is recommended based on age. However, consider renal function.

Renal_impairment

Initiation not recommended in eGFR <20 mL/min/1.73m². Continue 10 mg once daily for eGFR ≥20 mL/min/1.73m².

How to Take

Take orally once daily in the morning, with or without food.

Mechanism of Action

Empagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor. By inhibiting SGLT2, it reduces reabsorption of filtered glucose in the renal proximal tubule, leading to increased urinary glucose excretion and thereby reducing blood glucose levels. It also causes osmotic diuresis, leading to a modest reduction in blood pressure and weight.

Pharmacokinetics

Onset

Within 30 minutes to 1 hour (glucose lowering).

Excretion

Approximately 41% renally excreted and 50% fecally excreted.

Half life

Approximately 12.4 hours.

Absorption

Rapidly absorbed, peak plasma concentrations reached in 1.5 hours.

Metabolism

Mainly metabolized by glucuronidation via UGT1A8, UGT1A3, UGT1A9, and UGT2B7.

Side Effects

Contraindications

History of serious hypersensitivity reaction to Empagliflozin or any excipients.
Patients with severe renal impairment (eGFR <20 mL/min/1.73m²), end-stage renal disease, or on dialysis.

Drug Interactions

Lithium

Empagliflozin may decrease serum lithium concentrations.

Diuretics

May increase the risk of dehydration and hypotension.

Insulin or Insulin Secretagogues

Increased risk of hypoglycemia, may require dose adjustment.

Storage

Store below 30°C in a dry place, away from light. Keep out of reach of children.

Overdose

In case of an overdose, symptomatic treatment should be initiated. Empagliflozin is not dialyzable.

Pregnancy & Lactation

Pregnancy: Use not recommended during the second and third trimesters. Lactation: Not recommended due to potential for serious adverse reactions in a breastfed infant.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

10 tablets per strip30 tablets per box

Shelf Life

Typically 24-36 months from manufacturing date.

Availability

Pharmacies, hospitals

Approval Status

Approved

Patent Status

Patent protected (for brand)

WHO Essential Medicine

Yes

Clinical Trials

Extensive clinical trials (e.g., EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, EMPA-KIDNEY) have demonstrated efficacy in glycemic control and cardiovascular/renal outcomes.

Lab Monitoring

Renal function (eGFR) before initiation and periodically thereafter.
Blood glucose levels (HbA1c).
Lipid profile (less common, but sometimes monitored).

Doctor Notes

Counsel patients on signs/symptoms of ketoacidosis and genital/urinary tract infections.
Assess renal function prior to initiation and periodically.
Caution with diuretics and in patients at risk for dehydration.

Patient Guidelines

Take as directed by your doctor.
Maintain a balanced diet and regular exercise.
Stay hydrated by drinking plenty of fluids.
Report any unusual symptoms, especially signs of urinary tract or genital infections, or ketoacidosis.
Do not stop taking without consulting your doctor.

Missed Dose Advice

If a dose is missed, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at once.

Driving Precautions

Empagliflozin itself does not affect the ability to drive, but patients should be aware of the risk of hypoglycemia (especially in combination with insulin or sulfonylureas) which might impair driving ability. Also, dizziness or dehydration can occur.